roubaixtuesday
Well-Known Member
- Joined
- 14 Dec 2019
- Messages
- 4,218
- Team supported
- City
Well, this is clearly false. The direct effectiveness has been measured, with clear statistical significance using symptomatic disease as an endpoint. Transmission reduction, as I understand it, can't be measured in such a trial and only assessed through the rollout. So you'd never assess this without approval. Very happy to be corrected if wrong on this.1. Effectiveness - protection directly to prevent disease & indirectly to reduce transmission. This cannot be assessed this quickly with any certainty, this is a roll of the dice in the short term as there has not been sufficient time/surveillance to assess this aspect which is the most crucial
2. I don't understand the point you're making, sorry.
Pharmacovigilance normally refers to monitoring through routine use, though formally includes clinical trial data. Of course this cannot be assessed long term - it's a new product. The reason conditional rather than formal approval is given is so trials can be mandated to continue. But approval of all treatments is on a risk/benefit basis. Most vaccine AEs are rapid at the point of administration. The risk - even for young, healthy people - of COVID infection is high.3. Side Effects - There is inadequate pharmacovigilance to ensure safety
These don't remotely add up to a "roll of the dice on many fronts". They are low probability, low impact scenarios. The worst case scenario is pretty trivial compared to the current pandemic, and is very unlikely.
Worst case scenarios being either low impact on transmission (vaccinated people are still protected), long term protection drops off (boosters required) or unknown high consequence low frequency long term adverse events.